Skip to main content
OpenTrials
Completed

NCT Number: NCT06133647

Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System

To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ductal Carcinoma in Situ Adenocarcinoma Breast Carcinoma In Situ Breast Diseases Breast Neoplasms Carcinoma Carcinoma in Situ Carcinoma, Intraductal, Noninfiltrating Carcinoma, Lobular Invasive Lobular Breast Carcinoma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Glandular and Epithelial Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Clinical Research Institute at Methodist Health System

Dallas, Texas, 75203, United States

About this study

Male breast cancer (MBC) is a rare disease without sufficient clinical data supporting the management and treatment. The treatment of MBC arises from data extrapolated from female breast cancer (FBC). MBC has higher mortality than FBC. Previous studies have suggested differences between MBC and FBC; however, treatments remain the same for both. Larger studies in MBC are needed to provide more clinical data to help guide treatment.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • • ≥ 18 years of age Patients diagnosed with ductal carcinoma in situ or invasive lobular carcinoma of the breast

Exclusion criteria

  • 18 years of age
  • Prisoners
  • Pregnant or breastfeeding

Treatment and study plan

managing Male Breast Cancer Patients at Methodist Health System

Procedure

To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).

Other names: Larger studies in MBC are needed to provide more clinical data to help guide treatment.

Primary outcomes

  1. Diagnosis Rates of patients with MBC and FBC

    Time frame: 13 years

    complications of treatment

  2. Recurrence rates of Patients with MBC and FBC

    Time frame: 13 years

    Recurrence rates of Patients with MBC and FBC

  3. Duration of remission in Patients with MBC and FBC

    Time frame: 13 years

    Duration of remission in Patients with MBC and FBC

  4. The Overall Survival of patients with MBC and FBC after receiving treatment

    Time frame: 13 years

    The Overall Survival of patients with MBC and FBC after receiving treatment

  5. Determine the complications of Treatment in patients with MBC and FBC

    Time frame: 13 years

    Determine the complications of Treatment in patients with MBC and FBC

Sponsors and collaborators

Lead sponsor

Methodist Health System

Other

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Nov 15, 2023
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.